NOVN.CH

119.52

+0.02%↑

NOVN.CH

119.52

+0.02%↑

NOVN.CH

119.52

+0.02%↑

NOVN.CH

119.52

+0.02%↑

NOVN.CH

119.52

+0.02%↑

Home・Elenco Azioni・Lonza Group AG
Search

Lonza Group AG

Aperta

SettoreSettore sanitario

494.8 0.22

Fortemente da comprare

Aggiornamento del prezzo 26 mag 2026, 08:05 UTC

AcquistaVendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

493.4

Massimo

497.4

Metriche Chiave

By Trading Economics

Entrata

57M

483M

Vendite

-621M

3B

P/E

Media del settore

35.968

49.701

Rendimento da dividendi

1.07

Margine di Profitto

16.345

Dipendenti

20,000

EBITDA

-181M

822M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+37.24% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

1.07%

2.39%

Utili prossimi

22 lug 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-6B

33B

Apertura precedente

494.58

Chiusura precedente

494.8

Notizie sul Sentiment di mercato

By Acuity

14%

86%

17 / 345 Classifica in Healthcare

Lonza Group AG Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 mar 2026, 17:44 UTC

Acquisizioni, Fusioni, Takeovers

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

DJ

LeggI

28 gen 2026, 06:15 UTC

Utili

Lonza Sales Grow on New Contract Momentum

DJ

LeggI

23 lug 2025, 08:30 UTC

Utili
I principali Market Mover

Lonza Shares Rise After Outlook Lift for Core Business

DJ

LeggI

15 mag 2026, 10:45 UTC

Discorsi di Mercato

Contract Drug Manufacturers to Benefit From U.S. Pharma Onshoring Push -- Market Talk

DJ

LeggI

8 mag 2026, 13:44 UTC

Discorsi di Mercato
Utili

Lonza Update Should Reassure on Outlook -- Market Talk

DJ

LeggI

9 mar 2026, 10:34 UTC

Discorsi di Mercato

Lonza Might Disappoint Investors With Capsule Business Valuation -- Market Talk

DJ

LeggI

6 mar 2026, 17:12 UTC

Acquisizioni, Fusioni, Takeovers

Correct: Lonza to Sell Capsules & Health Ingredients Business to Lone Star Funds

DJ

LeggI

6 mar 2026, 17:10 UTC

Acquisizioni, Fusioni, Takeovers

Lonza: Total Undiscounted Proceeds Expected to Be at or Above CHF3B

DJ

LeggI

6 mar 2026, 17:09 UTC

Acquisizioni, Fusioni, Takeovers

Lonza to Retain 40% Stake in CHI

DJ

LeggI

6 mar 2026, 17:08 UTC

Acquisizioni, Fusioni, Takeovers

Lonza Will Receive Upfront Proceeds of CHF1.7B

DJ

LeggI

6 mar 2026, 17:07 UTC

Acquisizioni, Fusioni, Takeovers

Lonza: Transaction Expected to Close in 2H

DJ

LeggI

6 mar 2026, 17:07 UTC

Acquisizioni, Fusioni, Takeovers

Lonza: This Is for Enterprise Value of CHF2.3B at Closing

DJ

LeggI

6 mar 2026, 17:06 UTC

Acquisizioni, Fusioni, Takeovers

Lonza to Sell Capsules & Health Ingredients Business Lone Star Funds

DJ

LeggI

28 gen 2026, 12:04 UTC

Discorsi di Mercato
Utili

Lonza Results Show a Company in Good Shape -- Market Talk

DJ

LeggI

28 gen 2026, 05:35 UTC

Utili

Lonza Anticipates 2026 Core EBITDA Margin to Reach Level Above 32%

DJ

LeggI

28 gen 2026, 05:34 UTC

Utili

Lonza Anticipates 2026 Sales Growth of 11-12% at CER

DJ

LeggI

28 gen 2026, 05:33 UTC

Utili

Lonza Issues 2026 View

DJ

LeggI

28 gen 2026, 05:32 UTC

Utili

Lonza 2025 Core Ebitda Margin 31.6%

DJ

LeggI

28 gen 2026, 05:32 UTC

Utili

Analysts Saw Lonza 2025 Core Ebitda at CHF2.27B

DJ

LeggI

28 gen 2026, 05:32 UTC

Utili

Lonza 2025 Core Ebitda CHF2.06B

DJ

LeggI

28 gen 2026, 05:30 UTC

Utili

Analysts Saw Lonza 2025 Sales at CHF7.54B

DJ

LeggI

28 gen 2026, 05:30 UTC

Utili

Lonza 2025 Sales CHF6.53B

DJ

LeggI

27 ott 2025, 08:24 UTC

Discorsi di Mercato

Lonza on Track to Meet Long-Term Goals -- Market Talk

DJ

LeggI

23 ott 2025, 10:53 UTC

Discorsi di Mercato
Utili

Lonza Set to Recover as Contracts Flow in -- Market Talk

DJ

LeggI

23 lug 2025, 08:00 UTC

Discorsi di Mercato
Utili

Lonza Nudges Up Full-Year Guidance for Core Business After Good Results -- Market Talk

DJ

LeggI

23 lug 2025, 04:44 UTC

Utili

Lonza 1H Sales Grew 19% at Constant Currency

DJ

LeggI

23 lug 2025, 04:43 UTC

Utili

Lonza 1H Core Ebitda Margin 29.6%

DJ

LeggI

23 lug 2025, 04:43 UTC

Utili

Lonza: Margins Will Be Only Minimally Affected

DJ

LeggI

23 lug 2025, 04:42 UTC

Utili

Lonza Expects FX Headwind of -2.5% to -3.5% on 2025 Sales and Core Ebitda

DJ

LeggI

23 lug 2025, 04:42 UTC

Utili

Lonza: This Is Mainly From Weakening of U.S. Dollar

DJ

LeggI

Confronto tra pari

Modifica del prezzo

Lonza Group AG Previsione

Obiettivo di Prezzo

By TipRanks

37.24% in crescita

Previsioni per 12 mesi

Media 676.33 CHF  37.24%

Alto 762 CHF

Basso 630 CHF

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Lonza Group AG - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

6

Acquista

0

Mantieni

0

Vendi

Basato sugli analisti di 6 che hanno fornito valutazioni azionarie a Lonza Group AG - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

17 / 345 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Altri titoli del settore

NOVN.CH

Novartis AG

119.52

↑ +0.02%
help-icon Live chat